Sjögren's Syndrome Clinical Trials

3 recruiting

Frequently Asked Questions

Common questions about Sjögren's Syndrome clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 3

A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

Sjögren's Syndrome
Amgen844 enrolled144 locationsNCT06747949
Recruiting
Phase 2

A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE

Sjögren's Syndrome
Lubris Bio Pty Ltd80 enrolled6 locationsNCT07118241
Recruiting
Phase 1

Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases

Relapsed/Refractory Systemic Lupus ErythematosusRelapsed/Refractory Systemic SclerosisRelapsed/Refractory Idiopathic Inflammatory Myopathies+3 more
Beijing Boren Hospital12 enrolled1 locationNCT07361094
Recruiting
Phase 1

A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome

Healthy VolunteersSjögren's Syndrome
Astellas Pharma Global Development, Inc.132 enrolled1 locationNCT06544642
Recruiting
Phase 2

Laser Acupuncture on Dry Eye and Sjögren's Syndrome-related Dry Eye Symptoms (LADESJS)

Dry Eye Syndrome (DES)Laser AcupunctureSjögren's Syndrome (SS)
Taipei Veterans General Hospital, Taiwan140 enrolled1 locationNCT06780293
Recruiting

Autoreactive Anti-Ro/SSA IgE To Determine Primary SjögRen's Syndrome's Disease Activity

Primary Sjögren's Syndrome
Centre Hospitalier Universitaire de Saint Etienne185 enrolled8 locationsNCT03003572
Recruiting
Phase 4

The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome

Primary Sjögren's Syndrome
Second Affiliated Hospital, School of Medicine, Zhejiang University78 enrolled1 locationNCT04981145